Report Information More information from: https ://www.wis eguyreports .com/reports /575871
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 Report / Search Code: WGR575871
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 28 June, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016’, provides in depth analys is on Human Papilloma Virus (HPV) E7 Protein targeted pipeline therapeutics . The report provides comprehens ive information on the Human Papilloma Virus (HPV) E7 Protein, targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Human Papilloma Virus (HPV) E7 Protein - The report reviews Human Papilloma Virus (HPV) E7 Protein targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Human Papilloma Virus (HPV) E7 Protein targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Human Papilloma Virus (HPV) E7 Protein targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Human Papilloma Virus (HPV) E7 Protein - Identify the us e of drugs for target identification and drug repurpos ing
- Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Human Papilloma Virus (HPV) E7 Protein development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 6 Lis t of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Human Papilloma Virus (HPV) E7 Protein Overview 9 Therapeutics Development 10 Human Papilloma Virus (HPV) E7 Protein - Products under Development by Stage of Development 10 Human Papilloma Virus (HPV) E7 Protein - Products under Development by Therapy Area 11 Human Papilloma Virus (HPV) E7 Protein - Products under Development by Indication 12 Human Papilloma Virus (HPV) E7 Protein - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Human Papilloma Virus (HPV) E7 Protein - Products under Development by Companies 15 Human Papilloma Virus (HPV) E7 Protein - Products under Development by Univers ities /Ins titutes 18 Human Papilloma Virus (HPV) E7 Protein - Therapeutics As s es s ment 20 As s es s ment by Monotherapy/Combination Products 20 As s es s ment by Route of Adminis tration 21 As s es s ment by Molecule Type 23 Human Papilloma Virus (HPV) E7 Protein - Companies Involved in Therapeutics Development 25 Advaxis , Inc. 25 AnGes MG, Inc. 26 Cancer Res earch Technology Limited 27 Etubics Corporation 28 Formune S.L. 29 Genexine, Inc. 30 Genticel S.A. 31 iBio, Inc. 32 Immunovaccine, Inc. 33 Inovio Pharmaceuticals , Inc. 34 Kite Pharma, Inc. 35 MedImmune, LLC 36 Selecta Bios ciences , Inc. 37 Tomegavax, Inc. 38 Trans gene SA 39 VLPbio 40 Human Papilloma Virus (HPV) E7 Protein - Drug Profiles 41 Antibodies to Target E7 for HPV As s ociated Cancer - Drug Profile 41 Product Des cription 41 Mechanis m Of Action 41 R& D Progres s 41 Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 42 Product Des cription 42 Mechanis m Of Action 42 R& D Progres s 42 axalimogene filolis bac - Drug Profile 43 Product Des cription 43 Mechanis m Of Action 43 R& D Progres s 43 BLSILSB-710c - Drug Profile 58 Product Des cription 58 Mechanis m Of Action 58 R& D Progres s 58 Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 59 Product Des cription 59 Mechanis m Of Action 59 R& D Progres s 59 CerviVax - Drug Profile 61
Product Des cription 61 Mechanis m Of Action 61 R& D Progres s 61 DPXE-7 - Drug Profile 62 Product Des cription 62 Mechanis m Of Action 62 R& D Progres s 62 EDA-HPVE7 - Drug Profile 63 Product Des cription 63 Mechanis m Of Action 63 R& D Progres s 63 ETBX-041 - Drug Profile 64 Product Des cription 64 Mechanis m Of Action 64 R& D Progres s 64 GLBL-101c - Drug Profile 65 Product Des cription 65 Mechanis m Of Action 65 R& D Progres s 65 GTL-001 - Drug Profile 67 Product Des cription 67 Mechanis m Of Action 67 R& D Progres s 67 GTL-002 - Drug Profile 70 Product Des cription 70 Mechanis m Of Action 70 R& D Progres s 70 GX-188E - Drug Profile 71 Product Des cription 71 Mechanis m Of Action 71 R& D Progres s 71 human papillomavirus [Serotype 16] vaccine - Drug Profile 72 Product Des cription 72 Mechanis m Of Action 72 R& D Progres s 72 human papillomavirus vaccine - Drug Profile 73 Product Des cription 73 Mechanis m Of Action 73 R& D Progres s 73 INO-3106 - Drug Profile 74 Product Des cription 74 Mechanis m Of Action 74 R& D Progres s 74 INO-3112 - Drug Profile 75 Product Des cription 75 Mechanis m Of Action 75 R& D Progres s 75 PVX-01 - Drug Profile 77 Product Des cription 77 Mechanis m Of Action 77 R& D Progres s 77 SEL-701 - Drug Profile 78 Product Des cription 78 Mechanis m Of Action 78 R& D Progres s 78 TA-CIN - Drug Profile 79 Product Des cription 79 Mechanis m Of Action 79 R& D Progres s 79 TG-4001 - Drug Profile 80 Product Des cription 80 Mechanis m Of Action 80 R& D Progres s 80 Vaccine for Cervical Cancer - Drug Profile 82 Product Des cription 82 Mechanis m Of Action 82 R& D Progres s 82 Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 83 Product Des cription 83 Mechanis m Of Action 83 R& D Progres s 83 VGX-3100 - Drug Profile 84 Product Des cription 84 Mechanis m Of Action 84 R& D Progres s 84 Vvax-001 - Drug Profile 87 Product Des cription 87 Mechanis m Of Action 87
R& D Progres s 87 Human Papilloma Virus (HPV) E7 Protein - Dormant Projects 88 Human Papilloma Virus (HPV) E7 Protein - Dis continued Products 90 Human Papilloma Virus (HPV) E7 Protein - Featured News & Pres s Releas es 91 Jun 15, 2016: Genticel to Pres ent Clinical Res ults of GTL001 at EUROGIN 2016 Congres s in Salzburg, Aus tria 91 Jun 15, 2016: Genticel to Pres ent Preclinical Res ults of GTL002 at EUROGIN 2016 Congres s in Salzburg, Aus tria 91 Jun 13, 2016: Genticel Announces Completion of Two Major Miles tones in Preparation for Phas e 3 Program of GTL001 91 Jun 08, 2016: Advaxis Announces Firs t Patient Dos ed in Phas e 2 Trial Evaluating AXAL in Anal Cancer 92 Jun 06, 2016: Advaxis Announces Updated Data at ASCO from a Phas e 2 Study of AXAL in Advanced Cervical Cancer Showing Promis ing Survival Rates Cons is tent with Earlier Reports 93 Jun 01, 2016: Genticel Announces Publication in ‘Clinical Cancer Res earch’ of Phas e 1 Trial Res ults Supporting Safety, Tolerability and Immunogenicity of GTL001 94 Apr 25, 2016: Phas e II Cervical Cancer Study with Advaxis ’ Axalimogene Filolis bac Selected for Pos ter Dis cus s ion Ses s ion at the 2016 ASCO Annual Meeting 95 Apr 20, 2016: Genticel Reports Additional Res ults at 12 Months From Phas e 2 Trial of HPV Immunotherapeutic Candidate, GTL001 96 Apr 20, 2016: New Preclinical Study Shows Immunovaccine’s DepoVax-bas ed Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors 97 Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phas e 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform 98 Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Bes t Therapeutic Vaccine” by World Vaccine Congres s 99 Mar 29, 2016: Advaxis Combination Trial with MedImmune Completes Firs t Dos eEs calation Cohort 100 Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 101 Mar 23, 2016: Advaxis Hos ts Res earch Reception to Review Late-Breaking AACR Abs tract 101 Mar 07, 2016: Dos ing Begins in High Dos e Expans ion Cohort in Phas e 2 Study of Axalimogene Filolis bac in Patients With Recurrent Cervical Cancer 102 Appendix 103 Methodology 103 Coverage 103 Secondary Res earch 103 Primary Res earch 103 Expert Panel Validation 103 Contact Us 103 Dis claimer 104 Lis t of Tables Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11 Number of Products under Development by Indication, H1 2016 12 Comparative Analys is by Late Stage Development, H1 2016 13 Comparative Analys is by Early Stage Products , H1 2016 14 Number of Products under Development by Companies , H1 2016 15 Products under Development by Companies , H1 2016 16 Products under Development by Companies , H1 2016 (Contd..1) 17 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 18 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 19 As s es s ment by Monotherapy/Combination Products , H1 2016 20 Number of Products by Stage and Route of Adminis tration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Pipeline by Advaxis , Inc., H1 2016 25 Pipeline by AnGes MG, Inc., H1 2016 26 Pipeline by Cancer Res earch Technology Limited, H1 2016 27 Pipeline by Etubics Corporation, H1 2016 28 Pipeline by Formune S.L., H1 2016 29 Pipeline by Genexine, Inc., H1 2016 30 Pipeline by Genticel S.A., H1 2016 31 Pipeline by iBio, Inc., H1 2016 32 Pipeline by Immunovaccine, Inc., H1 2016 33 Pipeline by Inovio Pharmaceuticals , Inc., H1 2016 34 Pipeline by Kite Pharma, Inc., H1 2016 35 Pipeline by MedImmune, LLC, H1 2016 36 Pipeline by Selecta Bios ciences , Inc., H1 2016 37 Pipeline by Tomegavax, Inc., H1 2016 38 Pipeline by Trans gene SA, H1 2016 39 Pipeline by VLPbio, H1 2016 40 Dormant Projects , H1 2016 88 Dormant Projects (Contd..1), H1 2016 89 Dis continued Products , H1 2016 90 Lis t of Figures Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11
Number of Products under Development by Top 10 Indication, H1 2016 12 Comparative Analys is by Early Stage Products , H1 2016 14 As s es s ment by Monotherapy/Combination Products , H1 2016 20 Number of Products by Routes of Adminis tration, H1 2016 21 Number of Products by Stage and Routes of Adminis tration, H1 2016 21 Number of Products by Molecule Types , H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 23
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349